GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Yew Bio-Pharm Group Inc (OTCPK:YEWB) » Definitions » Debt-to-EBITDA

Yew Bio-Pharm Group (Yew Bio-Pharm Group) Debt-to-EBITDA : -3.06 (As of Sep. 2021)


View and export this data going back to 2013. Start your Free Trial

What is Yew Bio-Pharm Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Yew Bio-Pharm Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $9.01 Mil. Yew Bio-Pharm Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $0.24 Mil. Yew Bio-Pharm Group's annualized EBITDA for the quarter that ended in Sep. 2021 was $-3.03 Mil. Yew Bio-Pharm Group's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2021 was -3.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Yew Bio-Pharm Group's Debt-to-EBITDA or its related term are showing as below:

YEWB's Debt-to-EBITDA is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 2.14
* Ranked among companies with meaningful Debt-to-EBITDA only.

Yew Bio-Pharm Group Debt-to-EBITDA Historical Data

The historical data trend for Yew Bio-Pharm Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yew Bio-Pharm Group Debt-to-EBITDA Chart

Yew Bio-Pharm Group Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.85 4.72 2.78 1.95

Yew Bio-Pharm Group Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 5.38 0.64 7.41 -3.06

Competitive Comparison of Yew Bio-Pharm Group's Debt-to-EBITDA

For the Farm Products subindustry, Yew Bio-Pharm Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Yew Bio-Pharm Group's Debt-to-EBITDA Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Yew Bio-Pharm Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Yew Bio-Pharm Group's Debt-to-EBITDA falls into.



Yew Bio-Pharm Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Yew Bio-Pharm Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.045 + 0.292) / 4.792
=1.95

Yew Bio-Pharm Group's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.012 + 0.242) / -3.028
=-3.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2021) EBITDA data.


Yew Bio-Pharm Group  (OTCPK:YEWB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Yew Bio-Pharm Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Yew Bio-Pharm Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Yew Bio-Pharm Group (Yew Bio-Pharm Group) Business Description

Traded in Other Exchanges
N/A
Address
9460 Telstar Avenue, Suite 6, El Monte, CA, USA, 91731
Yew Bio-Pharm Group Inc is a grower and seller of yew trees and manufacturer of products made from yew trees in China. The company also sells raw material, including the branches and leaves of yew trees, used in the manufacturing of traditional Chinese medicines, which are used as a secondary treatment for certain cancers, meaning they must be administered in combination with other pharmaceutical drugs. The company operating business segments are China and the United States, of which the majority of its revenue comes from China.
Executives
Yongchun Shi director 9460 TELSTAR AVENUE, SUITE 6 EL MONTE CA 91302
Xiefeng Liu director 9460 TELSTAR AVENUE, SUITE 6 EL MONTE CA 91731
Guoshuang Tian director 9460 TELSTAR AVENUE, SUITE 6 EL MONTE CA 91731
Xuehai Wu director 9460 TELSTAR AVENUE, SUITE 6 EL MONTE CA 91731
Xingming Han director DOOR 3, FLOOR 7, VIC NO.23 TONGZHAN ST. XIANGFANG DISTRICT HARBIN CITY F4 XXXXXXXXX
Adam C Wasserman officer: Chief Financial Officer 1643 ROYAL GROVE WAY, WESTON FL 33327
Guifang Qi director, officer: Treasurer 501 N. MOORE AVE. APT. A MONTEREY PARK CA 91754
Zhiguo Wang director, officer: President and Secretary NO. 234, GEXIN STREET NANGANG DISTRICT HARBIN CITY F4 XXXXXXXXX

Yew Bio-Pharm Group (Yew Bio-Pharm Group) Headlines

From GuruFocus

Yew Bio-Pharm Group Announces New Significant Agreement

By Marketwired Marketwired 09-12-2018

Yew Bio-Pharm Group Announces New Cosmetic Subsidiary

By Marketwired Marketwired 03-09-2021